Home
About
Overview
Sharing Data
ORCID
Help
History (41)
Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events.
Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin.
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
See All 41 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? Ther Adv Med Oncol. 2023; 15:17588359231198446.
View in:
PubMed
authors with profiles
Jessica Donington
James Dolezal
Everett Vokes
Marina Chiara Garassino
Christine Bestvina
Robert Cameron